GLP3-R / GLP2-T Blend

"GLP3-R / GLP2-T" is vendor shorthand, not official nomenclature: in research-supplier catalogs, "GLP-2 T" denotes tirzepatide and "GLP-3 R" denotes retatrutide — informal market codes that rank the compounds by generation rather than by biology. The naming deserves a caution flag, because physiological GLP-2 (glucagon-like peptide-2) is a real and entirely different hormone — an intestinotrophic peptide studied for gut-mucosal growth — and "GLP-3" does not exist as an endogenous hormone at all. What this blend actually pairs is two synthetic incretin-receptor agonists: tirzepatide, a 39-amino-acid dual agonist engineered on a GIP backbone that activates both the GIP and GLP-1 receptors, and retatrutide (LY3437943), a triple agonist that adds glucagon-receptor activity to GIP/GLP-1 agonism. In published clinical research these two compounds produced the largest weight-reduction signals recorded in the incretin literature — tirzepatide up to approximately 20.9% mean body-weight reduction at 72 weeks in the SURMOUNT-1 trial, and retatrutide up to approximately 24.2% at 48 weeks in its Phase 2 trial — which is why combined-format research listings like this one have appeared on the supplier market.

For laboratory researchers the combined format raises a documentation requirement stricter than for single-compound vials: the label on this listing reads 30MG/5MG, and a certificate of analysis with per-compound mass-spectrometry identification is the only way to confirm which mass corresponds to which peptide and whether the two are co-lyophilized in a single vial or supplied separately. Receptor-pharmacology studies should also account for the compounds' overlapping GIP/GLP-1 activity: in a co-exposure design their individual receptor contributions cannot be separated without arm-level controls.

Peptides.SO currently tracks 2 supplier listings for this blend format, from Southern Aminos ($169.00) and Glow Aminos ($240.00) — a 42% price spread on the same labeled format, which makes COA quality and testing documentation the deciding variable rather than price alone. Researchers can also compare the standalone retatrutide and tirzepatide listings tracked on this platform to price the blend against sourcing each compound separately.

Potential Research Applications: Incretin-receptor pharmacology (GIP, GLP-1, and glucagon receptor co-activation) Comparative dual- vs. triple-agonist signaling research Adipose and hepatic lipid-metabolism pathway research in preclinical models Receptor-desensitization and combination-exposure study designs Analytical method development for multi-peptide formulation verification

Cited Research: Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PubMed PMID: 37366315. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PubMed PMID: 35658024.

For laboratory research only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.